Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
BridgeBio Pharma’s Partnership with Kyowa Kirin
Orionis Biosciences’ Collaboration with Genentech
Goodwin Procter advised Orionis Biosciences on the collaboration with Genentech. Privately held Orionis Biosciences announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover...
Seagen and Nurix’s Strategic Collaboration
Goodwin advised Seagen on the deal. Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that it has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc....
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Coherus’ Acquisition of Surface Oncology
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
Quest Diagnostics’ Acquisition of Haystack Oncology
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
OncoC4’s Strategic Collaboration with BioNTech
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
Q32 Bio’s Collaboration and Option Agreement with Horizon Therapeutics Ireland DAC
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
BridgeBio Pharma’s License Agreement with Bristol Myers Squibb
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
Sanofi’s Exclusive Collaboration with Seagen
Arnold & Porter advised Sanofi on the deal while Goodwin Procter represented Seagen. Sanofi announced its exclusive collaboration with Nasdaq-listed biotech Seagen Inc. to design, develop and...
Tessera Therapeutics’ Collaboration with Serotiny
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its collaboration with Serotiny to engineer programmable Gene Writer proteins. Under the terms of the agreement, Serotiny...